120 related articles for article (PubMed ID: 637906)
21. Use of high-dose oral methotrexate sequenced at 24 hours with 5-FU: a clinical toxicity study.
Benz C; Silverberg M; Cadman E
Cancer Treat Rep; 1983 Mar; 67(3):297-9. PubMed ID: 6831477
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
23. Clinical pharmacologic effects of thymidine plus 5-FU.
Ohnuma T; Roboz J; Waxman S; Mandel E; Martin DS; Holland JF
Cancer Treat Rep; 1980; 64(12):1169-77. PubMed ID: 7471111
[TBL] [Abstract][Full Text] [Related]
24. Thymidine arrest and synchrony of cellular growth in vivo.
Kufe DW; Egan EM; Rosowsky A; Ensminger W; Frei E
Cancer Treat Rep; 1980; 64(12):1307-17. PubMed ID: 7471121
[TBL] [Abstract][Full Text] [Related]
25. Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion.
Trump DL; Tutsch KD; Koeller JM; Tormey DC
Cancer Res; 1985 Jun; 45(6):2853-8. PubMed ID: 3986812
[TBL] [Abstract][Full Text] [Related]
26. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
27. [High dose methotrexate with leucovorin rescue in the treatment of malignant lymphoma].
Sampi K; Hattori M
Gan To Kagaku Ryoho; 1982 Jul; 9(6):1068-73. PubMed ID: 6985194
[TBL] [Abstract][Full Text] [Related]
28. [High dose methotrexate with CF rescue therapy in patients with head and neck cancer].
Inuyama Y; Taketa C; Hiroto I; Fujii M; Takaoka T; Tanaka J; Matsuura S; Satake B; Takeoda S; Nishijima W
Gan To Kagaku Ryoho; 1984 Sep; 11(9):1823-31. PubMed ID: 6332576
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic studies during phase I trials of high-dose thymidine infusions.
Zaharko DS; Bolten BJ; Chiuten D; Wiernik PH
Cancer Res; 1979 Dec; 39(12):4777-81. PubMed ID: 498107
[TBL] [Abstract][Full Text] [Related]
30. Resistance of human bone marrow CFUC to high-dose methotrexate cytotoxicity.
Koizumi S; Yamagami M; Ueno Y; Miura M; Taniguchi N
Exp Hematol; 1980 May; 8(5):635-40. PubMed ID: 7461061
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
Lyass O; Hubert A; Gabizon AA
Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
[TBL] [Abstract][Full Text] [Related]
32. Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy.
Eleff M; Franks PE; Wampler GL; Collins JM; Goldman ID
Cancer Treat Rep; 1985; 69(7-8):867-74. PubMed ID: 2410122
[TBL] [Abstract][Full Text] [Related]
33. Preoperative administration of high-dose methotrexate for osteosarcoma.
Chan KW; Knowling MA; Duncan CP; Morton KS
Can J Surg; 1984 May; 27(3):305-7, 309. PubMed ID: 6586272
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of high-dose etoposide phosphate in man.
Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
[TBL] [Abstract][Full Text] [Related]
35. Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
Schilsky RL; O'Laughlin K; Ratain MJ
Cancer Res; 1986 Aug; 46(8):4184-8. PubMed ID: 3731086
[TBL] [Abstract][Full Text] [Related]
36. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
[TBL] [Abstract][Full Text] [Related]
37. Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue.
Henderson IC; Gelman R; Canellos GP; Frei E
Cancer Treat Rep; 1981; 65 Suppl 1():67-75. PubMed ID: 6976832
[TBL] [Abstract][Full Text] [Related]
38. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
[TBL] [Abstract][Full Text] [Related]
39. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
40. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
